Top

Published in:

01-06-2008 | Topic Paper

The role of lymphadenectomy in high risk prostate cancer

Authors: Fiona C. Burkhard, Urs E. Studer

Published in: World Journal of Urology | Issue 3/2008

Abstract

Historically, patients with high risk prostate cancer were considered poor candidates for radical prostatectomy (RP) due to the likelihood of positive pelvic lymph nodes and decreased long term survival. Although there is still no consensus on the optimal therapy for this group of patients, there is increasing evidence that surgery could play a role. Cancer specific survival (CSS) rates after RP for locally advanced disease at 10 year follow up range from 29 to 72%, depending on tumor differentiation. The role of pelvic lymph node dissection (PLND) in prostate cancer remains a controversial topic. Nonetheless, in conjunction with RRP extended PLND (ePLND) should be performed as extended lymph node dissection in lieu of standard PLND may increase staging accuracy, influence decision making with respect to adjuvant therapy and possibly impact outcome. High risk patients with organ confined prostate cancer and low volume (micro)metastatic disease may be the ones to profit most from this approach.

Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32:385–390PubMed

Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW (2004) Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 172:1835–1839PubMedCrossRef

Lerner SE, Blute ML, Zincke H (1995) Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154:1447–1452PubMedCrossRef

van den Ouden D, Hop WC, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392–1397PubMedCrossRef

Messing E, Manola J, Sarosdy M, Wilding G, Crawford D, Trump D (2003) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer; results at 10 years of EST 3886. J Urol 169:396

D’Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW (2000) Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. Jama 284:1280–1283PubMedCrossRef

Scardino P (2005) Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3(Suppl 1):S29–S33PubMed

Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131PubMedCrossRef

Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499 (discussion 499)PubMedCrossRef

10.

D’Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:56–61PubMedCrossRef

11.

Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521–1527PubMedCrossRef

12.

Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ (2007) Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70:685–690PubMedCrossRef

13.

Bader P, Spahn M, Huber R, Echtle D, Frohneberg D (2004) Limited lymph node dissection in prostate cancer may miss lymph node metastasis and determines outcome of apparently pN0 prostate cancer. Eur Urol 3:16 (A 55)

14.

Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121–125PubMedCrossRef

15.

Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98:788–793PubMedCrossRef

16.

Mattei A, Fuechsel FG, Dhar NB, Warncke SH, Thalmann GN, Krause T, Studer UE (2007) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53:118–125PubMedCrossRef

17.

Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G, Poulsen J (2003) Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high-risk” prostate cancer compared to MRI or CT. Scand J Urol Nephrol 37:382–386PubMedCrossRef

18.

Cabanas RM (1977) An approach for the treatment of penile carcinoma. Cancer 39:456–466PubMedCrossRef

19.

Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166:1715–1719PubMedCrossRef

20.

Bader P, Burkhard FC, Markwalder R, Studer UE (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514–518 (discussion 518)PubMedCrossRef

21.

Heidenreich A, Varga Z, Olbert P, Hofmann R (2001) Radical pelvic lymphadenectomy in clinically localised prostate cancer: high frequency of atypical metastasis. Eur Urol 39(suppl. 5):135 (A 530)

22.

Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M (2004) Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 171:2268–2271PubMedCrossRef

23.

Mattei A, Fuechsel FG, Warncke S, Z’Brun S, Baermann C, Krause TM, Studer UE (2005) Advantages of preoperative imaging with Technetium-99m-nanocolloid for prostate-sentinel-lymph-node-adenectomy: accuracy and surgical detection time using presurgical imaging guidance prior to gamma-probe-detection versus gamma-probe detection alone. J Urol 173:433CrossRef

24.

Gronau E, Weckermann D, Harzmann R (2005) Sentinel lymph node resection in prostate cancer patients with a PSA higher than 20 ng/ml. J Urol 173:437

25.

Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499PubMedCrossRef

26.

Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686PubMedCrossRef

27.

Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Markl B, Gordijn R, Harzmann R (2003) The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43:132–137PubMedCrossRef

28.

Stone NN, Stock RG, Unger P (1997) Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158:1891–1894PubMedCrossRef

29.

Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N, Smith JA Jr (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145–147 (discussion 147–148)PubMedCrossRef

30.

DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173:1121–1125PubMedCrossRef

31.

Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA, Scardino PT (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175:1320–1324 (discussion 1324–1325)PubMedCrossRef

32.

Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M et al (2006) Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24:3081–3088PubMedCrossRef

33.

Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M (2007) Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13:1192–1197PubMedCrossRef

34.

Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ (2006) Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735–2742PubMedCrossRef

35.

Golimbu M, Morales P, Al-Askari S, Brown J (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617–620PubMed

36.

Catalona WJ, Miller DR, Kavoussi LR (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 140:540–543PubMed

37.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. Jama 281:1591–1597PubMedCrossRef

38.

Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849–854PubMedCrossRef

39.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864–870 (discussion 870–861)PubMedCrossRef

40.

Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172:2252–2255PubMedCrossRef

41.

Campbell SC, Klein EA, Levin HS, Piedmonte MR (1995) Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 46:352–355PubMedCrossRef

Title: The role of lymphadenectomy in high risk prostate cancer
Authors: Fiona C. Burkhard
Urs E. Studer
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2008
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-008-0251-6

2024 ASCO Annual Meeting

Springer Medicine

The role of lymphadenectomy in high risk prostate cancer

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability

Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer

The management of high-risk prostate cancer in 2008

Substratification of high-risk localised prostate cancer treated by radical prostatectomy

The face of high risk prostate cancer

Curcumin protects against ischemia/reperfusion injury in rat kidneys